Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnesium acetate + dextrose monohydrate + sodium chloride + potassium acetate is a **sterile intravenous multiple-electrolyte and carbohydrate solution** marketed as **Normosol-M and 5% Dextrose Injection** and manufactured by ICU Medical. It contains dextrose monohydrate together with sodium, potassium, magnesium, chloride, and acetate sources, and is used for **parenteral maintenance of routine daily fluid and electrolyte requirements with minimal carbohydrate calories**. Its pharmacologic effect is not mediated through a single receptor or enzyme target; rather, it acts by **replacing water, electrolytes, and a small caloric source**, helping maintain extracellular fluid composition, acid-base balance through acetate metabolism to bicarbonate, and magnesium repletion during prolonged parenteral therapy when needed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium acetate + dextrose monohydrate + sodium chloride + potassium acetate.